Skip to main content

Table 3 Rate Differences (events/10.000 person-years [95% confidence interval]) for all-cause mortality and CVD endpoints after a 5-year follow-up by HbA1c categories

From: Mortality and cardiovascular disease burden of uncontrolled diabetes in a registry-based cohort: the ESCARVAL-risk study

  C / NC Total mortality C / NC CHD hospitalization C / NC Stroke hospitalization
eGFR   Model 1 Model 2   Model 1 Model 2   Model 1 Model 2
<  6 116 / 4188 Ref. Ref. 169 / 4135 Ref. Ref. 161 / 4143 Ref. Ref.
6–6.5 80 / 3693 −13.26
(−32.40, 5.88)
−11.44
(−30.75, 7.86)
154 / 3619 11.71
(−13.33, 36.74)
11.41
(−13.57, 36.39)
166 / 3607 24.14
(−1.22, 49.50)
22.30
(−3.16, 47.77)
6.5–7 72 / 3267 − 12.42
(− 32.08, 7.23)
−6.93
(−26.87, 13.02)
155 / 3184 28.06
(−0.06, 56.17)
25.04
(− 3.36, 53.45)
126 / 3213 3.64
(−22.45, 29.74)
0.10
(−26.13, 26.32)
7–7.5 60 / 2339 −5.34
(−27.81, 17.13)
4.24
(−18.73, 27.20)
123 / 2276 39.60
(7.54, 71.66)
37.34
(4.92, 69.76)
90 / 2309 − 0.06
(− 27.92, 27.81)
−4.88
(− 33.34, 23.57)
> = 7 171 / 5154 28.26
(9.17, 47.36)
34.22
(14.55, 53.90)
311 / 5014 72.24
(46.83, 97.64)
70.26
(44.43, 96.09)
243 / 5082 42.74
(18.58, 66.90)
35.15
(10.51, 59.79)
P-trend   0.001 < 0.001   < 0.001 < 0.001   0.007 0.044
  1. Model 1 is adjusted for age and sex. Model 2 is further adjusted smoking status (never, former, current), obesity (no, yes), hypertension (no, yes), chronic kidney disease (no, yes), HDL cholesterol ≤40 for men and ≤ 50 for women (no, yes), LDL ≥ 130 mg/dL (no, yes), anti-hypertensive medication (no, yes), glucose lowering medication (no, yes), lipid lowering medication (no, yes)